NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed a distribution deal for its SelectMDx for Prostate Cancer test in Spain with pharmaceutical company Ferrer.
Under the terms of the five-year exclusive deal, 10 Ferrer sales representatives will sell SelectMDx directly to 1,000 urologists in Spain. Samples will be sent to MDxHealth's laboratory in Nijmegen, the Netherlands for analysis. The agreement takes effect in January 2018.
Additional terms of the deal were not disclosed.